Clinical Efficacy and Safety Analysis of Glucocorticoids plus Immunosuppressive Agents for Systemic Lupus Erythematosus and its Influence on N-Glycan

To evaluate the clinical efficacy and safety of glucocorticoids plus immunosuppressive agents for systemic lupus erythematosus. Between March 2018 2022, 72 erythematosus patients were recruited assigned to receive either (control group) or drugs (observation via random number table method. Outcome measures included efficacy, safety, disease activity index score, immunoglobulin, complement factor C3/C4 levels N-glycan changes. After intervention, scores urine protein observation group lower than those control resulted in significantly decreased higher treatment efficiency (χ2=1.424, p=0.033) vs. alone (p<0.05). The difference incidence adverse events between two groups did not come up statistical standard (p>0.05). Patients showed C3 at 6 mo 9 after therapy C4 3 There was no significant (p>0.05) antibody groups. Immunosuppressive provide therapeutic benefits management by lowering serum immune levels, improving immunological function increasing factors with consistent safety. Despite this modality, future studies larger samples are encouraged further high-quality evidence-based evidence.